title: Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.
abstract: The aim of this study was to investigate whether combination therapy of alpha-glucosidase inhibitor and a sulfonylurea (SU) drug can prolong the duration of good glycemic control compared with SU alone in patients with type 2 diabetes. The open prospective study included 124 Japanese patients with type 2 diabetes and inadequate glycemic control (hemoglobin A(1c) [HbA(1c)] gt; 7.0%). Patients were given either voglibose plus a SU compound (glibenclamide or gliclazide, n = 61) or SU drug alone (n = 63). The first 6-month run-in period (targeted to HbA(1c) </= 7.0%) was followed by treatment for 3 years. The endpoint was deterioration of glycemic control (HbA(1c) >/= 8.0%). Fifty patients on combination therapy and 48 patients on SU alone completed the trial. During the follow-up, 21 patients on combination therapy and 30 patients on SU alone showed deterioration of glycemic control and reached the endpoint (P =.04). The combination therapy significantly prolonged the duration of good glycemic control (HbA(1c) < 8.0%) compared with SU alone by Kaplan-Meier estimated survival analysis using a log-rank test (P =.02). Thus, combination therapy with voglibose and a SU agent prolongs the duration of good glycemic control compared with SU alone in patients with type 2 diabetes.
authors.affiliation: Department of Diabetes and Metabolism, Endocrinology, and Rheumatology, Sasebo Chuo Hospital, Nagasaki, Japan.
authors.forename: Kazunari
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Sera
authors.forename: Yasuyo
authors.initials: Y
authors.lastname: Abe
authors.forename: Tan
authors.initials: T
authors.lastname: Tominaga
authors.forename: Yukitaka
authors.initials: Y
authors.lastname: Ueki
authors.forename: Seibei
authors.initials: S
authors.lastname: Miyake
mesh_terms: D001786:Blood Glucose / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use*; D005905:Glyburide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007294:Inositol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D004791:Enzyme Inhibitors; D005907:Gliclazide; D005905:Glyburide; D006442:Glycated Hemoglobin; D065089:Glycoside Hydrolase Inhibitors; D007294:Inositol; D013453:Sulfonylurea Compounds; C102817:voglibose